UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Nov

    03

    U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

    Sep

    09

    TK2d Awareness Day: The complexity of this rare, genetic mitochondrial disease and its impact on daily living can no longer be overlooked